MEET THE TEAM : EARLY STAGE RESEARCHERS

Alessandro Colombano

Alessandro Colombano

ESR1

View CV

Host Institution:
University of Aberdeen

Project:
WP4 ‘Fatty acid analogues and CPT1 inhibitors as PET tracers for cardiac dysfunction’

Main Supervisor:
Professor Matteo Zanda

Secondment:
6 months at AstraZeneca, Sweden (month 12)

Secondment Supervisor:
Dr Charles Elmore

Ilaria Patruno

Ilaria Patruno

ESR2

View CV

Host Institution:
University of Aberdeen

Project:
WP4 ‘Development of immuno-PET directed to thrombospondin 2 (TSP-2) for identification of hypertrophic responses of the left ventricle’

Main Supervisor:
Professor Matteo Zanda

Secondment:
3 months at STICHTING VU-VUMC, AMS, (month 30)

Secondment Supervisor:
Professor Bert Windhorst

Antonia Hognasbacka

Antonia Hognasbacka

ESR3

View CV

Host Institution:
STICHTING VU-VUMC, Amsterdam, The Netherlands

Project:
WP1 ‘Small-molecule tyrosine kinase inhibitors (TKI) PET in oncology and neurology’

Main Supervisor:
Prof. Bert Windhorst (STICHTING VU-VUMC)

Secondment:
3 months at University of Bergen, Norway (month 9)
6 months at Imanova, UK, (month 18)

Secondment Supervisor:
Professor Hans-Rene Bjorsvik (BER)
Dr Jan Passchier (IMA)

Marion Chomet

Marion Chomet

ESR4

View CV

Host Institution:
STICHTING VU-VUMC, Amsterdam, The Netherlands

Project:
WP1 ‘Reverse translational of Immuno-PET in oncology.’

Main Supervisor:
Professor Bert Windhorst

Secondment:
6 months at University of Aberdeen, UK (month 26) 2 months at VRIJE UNIVERSITEIT BRUSSEL BRU Belgium, (month 33)

Secondment Supervisor:
Professor Matteo Zanda (ABD)
Professor Vicky Caveliers (BRU)

ESR5

View CV

Host Institution:

VRIJE UNIVERSITEIT BRUSSEL BRU Belgium

Project:

WP2 ‘Development of [18F]-FDR-nanobodies for clinical translation.’

Main Supervisor:

Professor Vicky Caveliers

Secondment:

4 months at University of Aberdeen, UK (month 7)

6 months at Imanova, UK, (month 24)

Secondment Supervisor:

Professor Matteo Zanda (ABD)

Dr Jan Passchier (IMA)

Jessica Bridoux

Jessica Bridoux

ESR6

View CV

Host Institution:
VRIJE UNIVERSITEIT BRUSSEL BRU Belgium

Project:
WP2 ‘Site-specific nanobody functionalisation as PET imaging and therapy –theranostic tool’

Main Supervisor:
Professor Vicky Caveliers

Secondment:
6 months at AstraZeneca, Sweden (month 22)

Secondment Supervisor:
Dr Charles Elmore

Irene Feiner

Irene Feiner

ESR7

View CV

Host Institution:
Asociacion CIC biomaGUNE, San Sebastian

Project: 
WP3 ‘Synthesis and preclinical investigation of boron-enriched gold nanoparticles: a pre-targeting approach to boron neutron capture therapy.’

Main Supervisor:
Professor Jordi Llop

Secondment:
6 months at University of Aberdeen, UK  (month 14)
4 months at IMANOVA, UK (month 35)

Secondment Supervisors:
Professor Matteo Zanda (ABD)
Dr Jan Passchier (IMA)

Matteo Faltracco

Matteo Faltracco

ESR9

View CV

Host Institution:
University of Bergen

Project:
WP1 ‘Novel probes for hypoxia and NTR-reporter gene imaging.’

Main Supervisor:
Professor Hans-René Bjørsvik

Secondment:
6 months at AstraZeneca, Sweden (month 18)

Secondment Supervisor:
Dr Charles Elmore

Davide Cirillo

Davide Cirillo

ESR10

View CV

Host Institution:
University of Bergen

Project:
WP5 ‘Synthesis of combined targeting molecules as 18F-tracers for PET and anticancer pro-drugs: investigation of tumor drug distribution’.

Main Supervisor:
Professor Hans-René Bjørsvik

Secondment:
6 months at Imanova, UK (month 29)

Secondment Supervisor:
Dr Jan Passchier

Beatrice Longo

Beatrice Longo

ESR13

View CV

Host Institution:
University of Aberdeen

Project:
WP3 ‘Click pre-targeted PET imaging of disease targeting antibodies.’

Main Supervisor:
Professor Matteo Zanda

Secondment:
6 months at STICHTING VU-VUMC, AMS, The Netherlands (month 24)

Secondment Supervisor:
Professor Bert Windhorst

Cinzia Marceddu

Cinzia Marceddu

ESR14

View CV

Host Institution:
Imanova Ltd, UK

Project:
Project: WP3 ‘Development of pre-targeting as platform technology for biomolecule labelling.’

Main Supervisor:
Dr Jan Passchier

Secondment:
3 months at University of Bergen, Norway (month 13)
3 months at WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER, Germany (month 25)
2 months each at ICL, (month 8) and (month 20)

Secondment Supervisor:
Professor Hans-Rene Bjorsvik (BER)
Professor Andreas Jacobs (MUN)

Markus Artlesmair

Markus Artlesmair

ESR15

View CV

Host Institution:
AstraZeneca plc, Sweden

Project:
Project: WP4 ‘Development of a radioligand and PET ligand for the MC4 receptor.’

Main Supervisor:
Dr Charles Elmore

Secondment:
6 months, Aberdeen University (Month 18)

Secondment Supervisor:
Professor Matteo Zanda

ESR PROJECTS

ESR1

‘Fatty acid analogues and CPT1 inhibitors as PET tracers for cardiac dysfunction.’
Host: ABD

ESR2

ESR2 ‘Development of immuno-PET directed to thrombospondin 2 (TSP-2) for identification of hypertrophic responses of the left ventricle.’
Host: ABD

ESR3

‘Small-molecule tyrosine kinase inhibitors (TKI) PET in oncology and neurology’.
Host: AMS

ESR4

‘Reverse translational of Immuno-PET in oncology.’
Host: AMS

ESR5

‘Development of [18F]-FDR-nanobodies for clinical translation.’
Host: BRU

ESR6

‘Site-specific nanobody functionalization as PET imaging and therapy –theranostic tool.’
Host: BRU

ESR7

‘Synthesis and preclinical investigation of boron-enriched gold nanoparticles: a pre-targeting approach to boron neutron capture therapy.’
Host: SAN

ESR8

’Development and evaluation of bispecific nanoparticles for T cell engagement (NanoBites): a targeted and multimodality approach to cancer therapy.’
Host: SAN

ESR9

‘Novel probes for hypoxia and NTR-reporter gene imaging.’
Host: BER

ESR10

‘Synthesis of combined targeting molecules as 18F-tracers for PET and anticancer pro-drugs: investigation of tumor drug distribution.’
Host: BER

ESR11

‘Multi-modal and multi-tracer imaging of inflammation in stroke’
Host: MUN

ESR12

‘Multimodal two-photon microscopy and PET/MR imaging of glioma growth & angiogenesis.’
Host: MUN

ESR13

‘Click pre-targeted PET imaging of disease targeting antibodies.’
Host: ABD

ESR14

‘Development of pre-targeting as platform technology for biomolecule labelling’
Host: IMA

ESR15

‘Development of a radioligand and PET ligand for the MC4 receptor.’
Host: AZ

ESR SUPERVISION

Each of the ESRs recruited by PET3D are assigned:

  • A main supervisor, the Beneficiary Scientist in Charge.
  • A co-supervisor in the same Institution.
  • An advisor at a different Institution, who periodically monitors the activity and progress of the ESRs research and training.
  • Secondment supervisor, the Scientist in Charge at the incoming institution will temporarily assume the role of supervisor, whereas the outgoing institution will maintain a close contact with the seconded ESR and will continue to monitor his/her activity by different means (tele/web-conferences, emails, etc. involving both ESR and local supervisors) in order to confirm that the research and training activities are developing in line with the programs.

Importance of non-academic contribution to the supervision

Non-academic contribution to ESRs supervision plays a pivotal role in PET3D. All 13 ESRs recruited by academic participants will spend six months of secondment at one of the two industrial non-academic sites, whereas 2 ESRs recruited directly by the industry beneficiaries IMA and AZ will spend 6 months of secondment at one or more academic sites.

Each ESR will design their Personal Career Development Plan (PCDP) with their host supervisor, then PCDPs will be discussed with co-supervisor and advisor, and finally agreed with the Supervisory Board.

ESR ELIGIBILITY & MOBILITY

Eligibility requirements for an Early Stage Researcher under the European Commission Horizon 2020 Early Stage Training Scheme:

To be eligible to be appointed as an Early Stage Researcher:

  • On appointment all ESRs will have than four years research experience and will not possess a PhD. This 4 year period is measured from the date of obtaining the degree which would formally entitle to embark on a doctorate.
  • On appointment all ESRs must not have resided or carried out their main activity (work, studies, etc.) in the country of appointment for more than twelve months in the three years immediately prior to your recruitment.

Mobility

In addition to salary, a mobility allowance is paid to all ESRs
Mobility is required to ensure that all students:

  • Have the opportunity to experience a research activity (chemistry, radiochemistry, pharmacology, physics, informatics, biology and medicine) in departments of excellence;
  • Follow network-wide multidisciplinary training activities at the general network training events/schools;
  • Acquire complementary Pharma-skills, not provided by the home/host beneficiary, at another beneficiary institution;

A minimum of one secondment is planned for each ESR

-

NEWS

IMPACT Article Published

    Link to ingentaconnect article.   The ESRs...

ESRs RECRUITED
 

More information can be found here: ESR...

-

EVENTS

S2 – School on Radiopharmaceuticals in Drug Discovery

20 - 22 September  2017   PET3D 2-day...

S1 School on Radiopharmaceutical Development

27 February - 03 March 2017 PET3D 5-day training...